Myopenia, a condition marked by abnormal muscle loss, affects people across all age groups. Though linked to various diseases ...

This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related ...

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

Rheumatoid arthritis and spondyloarthritis are long-lasting inflammatory diseases that gradually wear down joints. While ...

Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

A new clinical test may be able to predict which biologic may be the most effective for each individual with rheumatoid ...

Exercise is another powerful tool—it improves circulation, reduces stress hormones, and boosts feel-good endorphins. Regular ...

Being diagnosed with a rheumatic disease is a life-altering experience that can feel overwhelming and intimidating. Rheumatic ...

Existing PIP claimants have been given peace of mind that they’ll be able to keep their benefit amid the welfare reform, ...

Due to the varying rates, you could receive just £29.20 per week if you only qualify for the lower rate of mobility. However, ...

DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).